<SEC-DOCUMENT>0001193125-16-664774.txt : 20160729
<SEC-HEADER>0001193125-16-664774.hdr.sgml : 20160729
<ACCEPTANCE-DATETIME>20160729170656
ACCESSION NUMBER:		0001193125-16-664774
CONFORMED SUBMISSION TYPE:	S-3ASR
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20160729
DATE AS OF CHANGE:		20160729
EFFECTIVENESS DATE:		20160729

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HERON THERAPEUTICS, INC. /DE/
		CENTRAL INDEX KEY:			0000818033
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				942875566
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3ASR
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-212784
		FILM NUMBER:		161794834

	BUSINESS ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		6503662626

	MAIL ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		STREET 2:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AP PHARMA INC /DE/
		DATE OF NAME CHANGE:	20010511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED POLYMER SYSTEMS INC /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3ASR
<SEQUENCE>1
<FILENAME>d224932ds3asr.htm
<DESCRIPTION>S-3ASR
<TEXT>
<HTML><HEAD>
<TITLE>S-3ASR</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on July&nbsp;29, 2016 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>FORM S-3
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:19pt; font-family:Times New Roman" ALIGN="center"><B>Heron Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>94-2875566</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>123 Saginaw Drive </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Redwood City, CA 94063 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(650) 366-2626 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address,
including zip code and telephone number, including area code, of Registrant&#146;s principal executive offices) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>David Szekeres
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Senior Vice President, General Counsel, Business Development and Secretary </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Heron Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>123 Saginaw Drive </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Redwood
City, California 94063 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(650) 366-2626 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Copy to: </I></B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Ryan A.
Murr </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Gibson, Dunn&nbsp;&amp; Crutcher LLP </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>555 Mission Street, </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Suite
3000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>San Francisco, CA 94105 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(415) 393-8200 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Approximate Date of
Commencement of Proposed Sale to the Public:</B> From time to time after the effective date of the Registration Statement as the registrant shall determine. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the
following box.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be
offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b)
under the Securities Act, please check the following box and list the Securities Act Registration Statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule
462(c) under the Securities Act, check the following box and list the Securities Act Registration Statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">If this Form is a registration statement pursuant to General
Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following
box.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment to a registration statement
filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following
box.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange
Act. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Title of Securities to be Registered (1)</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Amount<BR>to be</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Registered (1)</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed<BR>Maximum<BR>Offering Price<BR>Per Unit (1)</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed<BR>Maximum<BR>Aggregate<BR>Offering Price (1)</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount of<BR>Registration Fee (2)</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common Stock, $0.01 par value per share</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Preferred Stock, $0.01 par value per share</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Warrants</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">There is being registered hereunder an indeterminate number of the securities of each identified class that may be issued by the registrant at various times and at indeterminate prices. Pursuant to Rule 416 under the
Securities Act of 1933, as amended, or the Securities Act, the shares being registered hereunder include such indeterminate number of shares of securities as may be issuable by the registrant with respect to the shares being registered hereunder as
a result of stock splits, stock dividends or similar transactions. In addition, securities registered hereunder may be sold separately or as units with other securities registered hereunder. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">In accordance with Rules 456(b) and 457(r) under the Securities Act, the registrant is deferring payment of all of the registration fees required in connection with this registration statement. Any registration fee will
be paid subsequently on a pay-as-you-go basis in accordance with Rule 457(r). </TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:20pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g224932g04j69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under this prospectus, we or any selling stockholder may offer and sell from time to time, in one or more offerings, an indeterminate number
of shares of our common stock, preferred stock, and warrants or any combination thereof, separately, together or in series. The warrants may be convertible into or exercisable or exchangeable for common stock or preferred stock and the preferred
stock may be convertible into or exchangeable for common stock. Each time securities are offered or sold pursuant to this prospectus, we will describe in a prospectus supplement the securities being offered and sold, as well as the specific terms of
the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The NASDAQ Capital Market under the symbol &#147;HRTX.&#148; On July&nbsp;28, 2016, the
last reported sale price on The NASDAQ Capital Market was $16.74 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus, any prospectus supplement
and the documents incorporated by reference in this prospectus and any prospectus supplement carefully before you invest. This prospectus may not be used to offer or sell any of our common stock, preferred stock or warrants unless accompanied by a
prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or any selling stockholder may offer these securities in amounts, at prices and on terms determined at the time
of offering. We or any selling stockholder may sell the securities directly to investors, through agents we select, or through underwriters and dealers we select. See &#147;Plan of Distribution&#148; in this prospectus. Each prospectus supplement
will provide the amount, price, terms and plan of distribution relating to the securities to be sold pursuant to such prospectus supplement. If agents, underwriters or dealers are used to sell the securities, we will name them and describe their
compensation in a prospectus supplement or sales agreement prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in
our securities involves certain risks. See &#147;<A HREF="#toc224932_4">Risk Factors</A>&#148; beginning on Page 5 of this prospectus and in the applicable prospectus supplement and any related free writing prospectus, and in the other documents
that are incorporated by reference into this prospectus or the applicable prospectus supplement, for certain risks you should consider. You should read the entire prospectus carefully before you make your investment decision. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is July 29, 2016 </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc224932_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc224932_2">NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc224932_3">ABOUT THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc224932_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc224932_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc224932_6">RATIO OF EARNINGS TO FIXED CHARGES </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc224932_6a">DESCRIPTION OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc224932_12">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc224932_7">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc224932_8">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc224932_9">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc224932_10">INFORMATION INCORPORATED BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc224932_11">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained or incorporated by reference into this prospectus and any
prospectus supplement or any free writing prospectus that we may provide to you. We have not authorized anyone to provide you with different information. You must not rely upon any unauthorized information or representation. You should not assume
that the information contained in this prospectus or any applicable prospectus supplement is accurate as of any date other than the date on the front cover of the prospectus or the prospectus supplement or that the information contained in any
document incorporated by reference is accurate as of any date other than the date of the document incorporated by reference. Our business, financial condition, results of operations and prospects may have changed since those dates. We are not making
offers to sell the securities in any jurisdiction in which an offer or solicitation is not authorized or permitted or in which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an
offer or solicitation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Heron Therapeutics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, the Heron logo, SUSTOL<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Biochronomer<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> are our trademarks. All other trademarks appearing or incorporated by reference into this prospectus and any applicable
prospectus supplement are the property of their respective owners. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc224932_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of an automatic shelf registration statement that we filed with the Securities and Exchange Commission, or the SEC, as
a &#147;well-known seasoned issuer&#148; as defined in Rule&nbsp;405 under the Securities Act of 1933, as amended, or the Securities Act. Under this shelf registration statement, we and/or selling stockholders may offer shares of our common stock
and preferred stock, various series of warrants to purchase common stock or preferred stock, or any combination thereof, from time to time in one or more offerings under this prospectus at prices and on terms to be determined by market conditions at
the time of offering. This prospectus only provides you with a general description of the securities we and/or selling stockholders may offer. Each time we and/or selling stockholders offer a type or series of securities under this prospectus, we
will provide a prospectus supplement to this prospectus that will contain more specific information about the securities being offered and specific terms of the offering. We may also authorize one or more free writing prospectuses to be provided to
you that may contain material information relating to these offerings. This prospectus may not be used to sell our securities unless accompanied by a prospectus supplement. Each such prospectus supplement and any related free writing prospectus that
we may authorize to be provided to you may also add, update or change information contained in this prospectus or in documents incorporated by reference into this prospectus. If there is any inconsistency between the information in this prospectus
and the applicable prospectus supplement or related free writing prospectus, you should rely on the prospectus supplement or any related free writing prospectus we may authorize to be provided to you. We urge you to carefully read this prospectus,
any applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under the headings &#147;Information Incorporated by Reference&#148; and &#147;Where You Can
Find Additional Information&#148; before you invest in our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor any selling stockholder have authorized anyone to
provide you with information in addition to or different from that contained in this prospectus, any applicable prospectus supplement and any related free writing prospectus. We take no responsibility for, and can provide no assurances as to the
reliability of, any information not contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus that we may authorize to be provided to you. This prospectus is an offer to sell only the securities
offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate only as
of the date on the front of the document (unless the information specifically indicates that another date applies) and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference,
regardless of the time of delivery of this prospectus, any applicable prospectus supplement or any related free writing prospectus, or any sale of a security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the
actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as
exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading &#147;Where You Can Find Additional Information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc224932_2"></A>NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements within the meaning of the federal securities laws. We make such forward-looking statements
pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. You can identify forward-looking statements by the use of the words &#147;believe,&#148; &#147;expect,&#148;
&#147;anticipate,&#148; &#147;intend,&#148; &#147;estimate,&#148; &#147;project,&#148; &#147;will,&#148; &#147;should,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;assume&#148; and other expressions that predict or indicate future events and
trends and which do not relate to historical matters. You should not rely on forward-looking statements, because they involve known and unknown risks, uncertainties and other factors, some of which are beyond our control. These risks, uncertainties
and other factors may cause our actual results, performance or achievements to be materially different from the anticipated future results, performance or achievements expressed or implied by the forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors that might cause these differences include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">estimates of the outcome of our New Drug Application (&#147;NDA&#148;) resubmission to the U.S. Food and Drug Administration (&#147;FDA&#148;) for SUSTOL<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
(granisetron) Injection, extended release (&#147;SUSTOL&#148;) and potential regulatory approval for and commercial launch of SUSTOL; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any limitations or unfavorable warning or cautionary language that the FDA may ultimately impose on the label for SUSTOL; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the anticipated progress of our current research and development programs for HTX-011, HTX-019 and any other research and development programs we may pursue, including the completion of ongoing clinical trials,
initiation of new clinical trials and preclinical testing and the results of clinical and stability studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the anticipated timing of our filing of the NDA for HTX-019; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether safety and efficacy results of our clinical trials and other required tests for approval provide data to warrant potential regulatory approval of SUSTOL or further development of any of our other product
candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if approved, the possibility that the FDA approval of SUSTOL or other future product candidates might entail post-marketing studies and our ability to meet these requirements within the mandated timelines;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if approved, our ability to comply with standard post-marketing requirements including U.S. federal advertising and promotion laws, federal and state anti-fraud and abuse laws, healthcare information privacy and
security laws, safety surveillance, and disclosure of payments or other transfers of value to healthcare professionals and entities for SUSTOL or other future product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if approved, the market conditions during the commercial launch of SUSTOL or other future product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully market, commercialize and achieve market acceptance for SUSTOL or other future product candidates, including our positioning relative to competing products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully develop and achieve regulatory approval for other future product candidates utilizing our proprietary Biochronomer<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> drug delivery
technology; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish key collaborations for our products and any other future product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully develop and commercialize any technology that we may in-license or products we may acquire; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unanticipated delays due to manufacturing difficulties, supply constraints or changes in the regulatory environment; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully establish and maintain key vendor relationships necessary to manufacture our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully operate in non-U.S. jurisdictions in which we may choose to do business, including compliance with applicable regulatory requirements and laws; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">uncertainties associated with obtaining and enforcing patents to protect our products, and our ability to successfully defend ourselves against unforeseen third-party infringement claims; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding our capital requirements; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain additional financing and raise capital as necessary to fund operations or pursue business opportunities. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any forward-looking statements in this prospectus reflect our current views with respect to future events or to our future financial
performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by
these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section entitled &#147;Risk Factors&#148; in this prospectus, as may be
updated from time to time by our future filings under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and discussed elsewhere in this prospectus and the documents incorporated by reference herein. You should carefully review
all of these factors. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements were based on information, plans and estimates as of the date of this prospectus, and except
as required by law, we assume no obligation to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus may also contain estimates, projections and other information concerning our industry, our business, and the markets for
certain diseases, including data regarding the estimated size of those markets. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or
circumstances may differ materially from events and circumstances reflected in this information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc224932_3"></A>ABOUT THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Unless the context requires otherwise, in this Prospectus, the &#147;Company,&#148; &#147;Heron&#148; &#147;we,&#148; &#147;us&#148; and
&#147;our&#148; refer to Heron Therapeutics, Inc. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Heron Therapeutics, Inc. is a biotechnology company focused on improving the lives
of patients by developing best-in-class medicines that address major unmet medical needs. We are developing novel, patient-focused solutions that apply our innovative science and technologies to already-approved pharmacological agents. Our goal is
to build on therapeutics with well-known pharmacology by improving their tolerability and efficacy as well as broadening their potential field of use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The NASDAQ Capital Market under the symbol &#147;HRTX.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were founded in February 1983 as a California corporation under the name AMCO Polymerics, Inc., or AMCO. AMCO changed its name to Advanced
Polymer Systems, Inc. in 1984 and was reincorporated in the state of Delaware in 1987. We changed our name to A.P. Pharma, Inc. in May 2001 and changed our name from A.P. Pharma, Inc. to Heron Therapeutics, Inc. in January 2014. Our executive
offices are located at 123 Saginaw Drive, Redwood City, California 94063 and our telephone number is (650)&nbsp;366-2626. Additional information regarding our company, including our audited financial statements and descriptions of our business, is
contained in the documents incorporated by reference in this prospectus. See &#147;Where You Can Find Additional Information&#148; on page 12 and &#147;Information Incorporated by Reference&#148; beginning on page 12. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc224932_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. Before you decide whether to purchase any of our securities, in addition to the
other information, documents or reports included in or incorporated by reference into this prospectus and any accompanying prospectus supplement or other offering materials, you should carefully consider the risk factors in the section entitled
&#147;Risk Factors&#148; in any prospectus supplement to this prospectus as well as in our most recent Annual Report on Form&nbsp;10-K and any subsequent Quarterly Reports on Form&nbsp;10-Q, which are incorporated by reference into this prospectus
and any prospectus supplement in their entirety, as the same may be amended, supplemented or superseded from time to time by our filings under the Exchange Act. For additional information, see the section entitled &#147;Where You Can Find Additional
Information.&#148; These risks could materially and adversely affect our business, results of operations, financial condition and prospects and could result in a partial or complete loss of your investment. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc224932_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds we receive from the sale of securities as set forth in the applicable prospectus supplement. Unless
otherwise set forth in a prospectus supplement, we will not receive any proceeds from the sale of securities by any selling stockholder. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc224932_6"></A>RATIO OF EARNINGS TO FIXED CHARGES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we offer preference equity securities under this prospectus, then we will, if required at that time, provide a ratio of combined fixed
charges and preference dividends to earnings in the applicable prospectus supplement for such offering or in a document that we file with the SEC and incorporate by reference in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc224932_6a"></A>DESCRIPTION OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Description of Capital Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a description of our common stock and a summary of our preferred stock. You should refer to our certificate of incorporation
and our bylaws for the actual terms of our capital stock. Copies of our certificate of incorporation and bylaws may be obtained as described under the heading &#147;Where You Can Find Additional Information&#148; in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are authorized to issue up to 77,500,000 shares of capital stock of which 75,000,000 shares are of common stock, par value $0.01 per share,
and 2,500,000 shares are of preferred stock, par value $0.01 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders. Subject to preferences that
may be applicable to any outstanding preferred stock, the holders of common stock are entitled to receive ratably all dividends, if any, as may be declared form time to time by our Board of Directors out of the funds legally available. In the event
of the liquidation, dissolution or winding up of the Company, the holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock, if any, then
outstanding. The common stock has no preemptive or conversion rights. There are no redemption or sinking fund provisions applicable to the common stock. All outstanding shares of common stock are fully paid and non-assessable, and the shares of
common stock to be issued upon completion of this offering will be fully paid and non-assessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2016,
36,348,695&nbsp;shares of our common stock were issued and outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transfer Agent and Registrar. </I>The transfer agent and
registrar for our common stock is Computershare Trust Company&nbsp;N.A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Listing. </I>Our common stock is currently listed on The
NASDAQ Capital Market under the symbol &#147;HRTX.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our certificate of incorporation, our Board of Directors has the authority, without further action by stockholders, to designate up to
2,500,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges, qualifications and restrictions granted to or imposed upon the preferred stock, including dividend rights, conversion rights, voting rights,
rights and terms of redemption, liquidation preference and sinking fund terms, any or all of which may be greater than the rights of the common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2016, no shares of preferred stock were issued and outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we issue preferred stock, we will fix the rights, preferences, privileges, qualifications and restrictions of the preferred stock of each
series that we sell under this prospectus and applicable prospectus supplements in the certificate of designations relating to that series. If we issue preferred stock, we will incorporate by reference into the registration statement of which this
prospectus is a part the form of any certificate of designations that describes the terms of the series of preferred stock we are offering before the issuance of the related series of preferred stock. We urge you to read the prospectus supplement
and any free writing prospectus related to any series of preferred stock we may offer, as well as the complete certificate of designations that contains the terms of the applicable series of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain Provisions Affecting Control of Heron Therapeutics </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Certificate of Incorporation and Bylaw Provisions</I>. Some provisions of Delaware law and our certificate of incorporation and bylaws
contain provisions that could make the following transactions more difficult: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acquisition of us by means of a tender offer; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acquisition of us by means of a proxy contest or otherwise; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">removal of our incumbent officers and directors. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions, summarized below, are
intended to discourage coercive takeover practices and inadequate takeover bids and to promote stability in our management. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our Board of
Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Undesignated Preferred Stock</I>. The ability to authorize undesignated preferred stock makes it possible for our Board of
Directors to issue one or more series of preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers
or delaying changes in control or management of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Advance Notice Procedures</I>. The advance notice procedures in our
bylaws with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders provide that notice of stockholder proposals must be timely given in
writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first
anniversary date of the annual meeting for the preceding year. Our bylaws specify the requirements as to form and content of all such stockholder notices. These requirements may have the effect of precluding stockholders from bringing proposals
relating to the nomination of candidates for election as directors or new business before the stockholders at an annual or special meeting.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware Anti-Takeover Statute</I>. We are subject to Section&nbsp;203 of the General Corporation Law of the State of Delaware. This law
prohibits a publicly held Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years following the date that the stockholder became an interested stockholder unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the
transaction commenced, excluding for purposes of determining the number of shares outstanding those shares owned by persons who are directors and also officers and by employee stock plans in which employee participants do not have the right to
determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on or subsequent to the date of the transaction, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the
affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;203
defines &#147;business combination&#148; to include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any merger or consolidation involving the corporation and the interested stockholder; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any sale, transfer, pledge or other disposition of 10% or more of our assets involving the interested stockholder; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in general, any transaction that results in the issuance or transfer by us of any of our stock to the interested stockholder; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an &#147;interested stockholder&#148; as an entity or person
beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Description of Warrants </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General
Description of Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants for the purchase of common stock, preferred stock or any combination of these
securities. Warrants may be issued independently or together with other securities and may be attached to or separate from any offered securities. Each series of warrants will be issued under a separate warrant agreement to be entered into between a
warrant agent and us. The warrant agent will act solely as our agent in connection with the warrants and will not have any obligation or relationship of agency or trust for or with any holders or beneficial owners of warrants. The following outlines
some of the general terms and provisions of the warrants that we may issue from time to time. Additional terms of the warrants and the applicable warrant agreement will be set forth in the applicable prospectus supplement. The following description,
and any description of the warrants included in a prospectus supplement, may not be complete and is subject to and qualified in its entirety by reference to the terms and provisions of the applicable warrant agreement, which we will file with the
SEC in connection with any offering of warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement relating to a particular issue of warrants exercisable for common stock or preferred stock will describe the terms of
the common stock warrants and preferred stock warrants, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the title of the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the offering price for the warrants, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the aggregate number of the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the designation and terms of the common stock or preferred stock that may be purchased upon exercise of the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the designation and terms of the securities that the warrants are issued with and the number of warrants issued with each security; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the date from and after which the warrants and any securities issued with the warrants will be separately transferable; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of shares and price of common stock or preferred stock that may be purchased upon exercise of a warrant; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the dates on which the right to exercise the warrants commences and expires; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, a discussion of material U.S. federal income tax considerations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">anti-dilution provisions of the warrants, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">redemption or call provisions, if any, applicable to the warrants; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any additional terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exercise of Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant will entitle the holder of the warrant to purchase at the exercise price set forth in the applicable prospectus supplement the
number of shares of common stock or preferred stock being offered. Holders may exercise warrants at any time up to the close of business on the expiration date set forth in the applicable prospectus supplement. After the close of business on the
expiration date, unexercised warrants will be void. Holders may exercise warrants as set forth in the prospectus supplement relating to the warrants being offered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until a holder exercises the warrants to purchase any securities underlying the warrants, the holder will not have any rights as a holder of
the underlying securities by virtue of ownership of warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc224932_12"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling stockholders are persons or entities that, directly or indirectly, have acquired or will from time to time acquire from us, our
securities. Such selling stockholders may be parties to registration rights agreements with us, or we otherwise may have agreed or will agree to register their securities for resale. The initial purchasers of our securities, as well as their
transferees, pledgees, donees or successors, all of whom we refer to as &#147;selling stockholders,&#148; may from time to time offer and sell our securities pursuant to this prospectus, any applicable prospectus supplement or post-effective
amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information regarding the beneficial ownership of our securities by a selling stockholder, the number of securities being
offered by a selling stockholder and the number of securities beneficially owned by a selling stockholder after the applicable offering, where applicable, will be set forth in a prospectus supplement or in a post-effective amendment. The applicable
prospectus supplement or post-effective amendment will also disclose whether any of the selling stockholders has held any position or office with, has been employed by or otherwise has had a material relationship with us during the three years prior
to the date of the applicable prospectus supplement or post-effective amendment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc224932_7"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities covered by this prospectus from time to time in one or more offerings. Registration of the securities covered by
this prospectus does not mean, however, that those securities will necessarily be offered or sold. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities separately
or together: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">through one or more underwriters or dealers in a public offering and sale by them; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">directly to investors; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">through agents. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities from time to time: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in one or more transactions at a fixed price or prices, which may be changed from time to time; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at market prices prevailing at the times of sale; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at prices related to such prevailing market prices; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at negotiated prices. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe the method of distribution of the securities issued
pursuant to this prospectus and the terms of the offering in the applicable prospectus supplement. Discounts or concessions allowed or re-allowed or paid to dealers may be changed from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If underwriters are used in the sale of any securities, the securities will be acquired by the underwriters for their own account and may be
resold from time to time in one or more transactions described above. The securities may be either offered to the public through underwriting syndicates represented by managing underwriters, or directly by underwriters. Generally, the
underwriters&#146; obligations to purchase the securities will be subject to conditions precedent and the underwriters will be obligated to purchase all of the securities if they purchase any of the securities. We may use underwriters with whom we
have a material relationship. We will describe in the applicable prospectus supplement, naming the underwriter, the nature of any such relationship. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may authorize underwriters, dealers or agents to solicit offers by certain purchasers to purchase the securities from us at the public
offering price set forth in the applicable prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. The contracts will be subject only to those conditions set forth in the
applicable prospectus supplement, and the applicable prospectus supplement will set forth any commissions we pay for solicitation of these contracts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters, dealers and agents may be entitled to indemnification by us against certain civil liabilities, including liabilities under the
Securities Act, or to contribution with respect to payments made by the underwriters, dealers or agents, under agreements between us and the underwriters, dealers and agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may grant underwriters who participate in the distribution of securities an option to purchase additional securities to cover
over-allotments, if any, in connection with the distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters, dealers or agents may receive compensation in the form of
discounts, concessions or commissions from us or our purchasers, as their agents in connection with the sale of securities. These underwriters, dealers or agents may be considered to be underwriters under the Securities Act. As a result, discounts,
commissions or profits on resale received by the underwriters, dealers or agents may be treated as underwriting discounts and commissions. The applicable prospectus supplement will identify any such underwriter, dealer or agent and describe any
compensation received by them from us. Any initial public offering price and any discounts or concessions allowed or re-allowed or paid to dealers may be changed from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in the applicable prospectus supplement, all securities we offer,
other than common stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without
notice. Any common stock sold pursuant to a prospectus supplement will be listed for trading on The NASDAQ Capital Market or other principal market for our common stock. We may apply to list any series of preferred stock or warrants on an exchange,
but we are not obligated to do so. Therefore, there may not be liquidity or a trading market for any series of securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
underwriter may engage in over-allotment transactions, stabilizing transactions, short-covering transactions and penalty bids in accordance with Regulation M under the Exchange Act. Over-allotment involves sales in excess of the offering size, which
create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market
after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a covering transaction to cover short
positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. We make no representation or prediction as to the direction
or magnitude of any effect that such transactions may have on the price of the securities. For a description of these activities, see the information under the heading &#147;Underwriting&#148; or &#147;Plan of Distribution&#148; in the applicable
prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters, broker-dealers or agents who may become involved in the sale of the common stock may engage in
transactions with and perform other services for us in the ordinary course of their business for which they receive compensation. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc224932_8">
</A>EXPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OUM&nbsp;&amp; Co. LLP, an independent registered public accounting firm, has audited our consolidated financial
statements included in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2015, as set forth in their report, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our consolidated
financial statements are incorporated by reference in reliance on OUM&nbsp;&amp; Co. LLP&#146;s report, given on their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc224932_9"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The legality of the issuance of the securities being offered hereby and the binding nature of any warrants being offered hereby is being
passed upon by Gibson, Dunn&nbsp;&amp; Crutcher LLP, San Francisco, California. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc224932_10"></A>INFORMATION INCORPORATED BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows the Company to &#147;incorporate by reference&#148; the information that is filed by the Company with the SEC, which means that
the Company can disclose important information to you by referring you to those documents. The documents incorporated by reference are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2015; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Portions of our Definitive Proxy Statement on Schedule 14A filed with the SEC on April&nbsp;29, 2016 that have been incorporated by reference into our Annual Report on Form 10-K for the year ended December&nbsp;31,
2015; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s Quarterly Report on Form 10-Q for the quarter ended March&nbsp;31, 2016; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s Current Reports on Form 8-K filed with the SEC on January 11, 2016, January&nbsp;15, 2016, January 22, 2016, January 29, 2016, February 29, 2016, March 3, 2016, April 15, 2016, April&nbsp;18, 2016,
and June 22, 2016; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The description of the Company&#146;s common stock contained in the registration statement on Form 8-A, as amended, filed with the SEC on January&nbsp;22, 2014 pursuant to Section&nbsp;12(b) of the Exchange Act,
including any amendment or report filed for the purpose of updating that description. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All documents we file with the SEC
pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, except as to any portion of any report or documents that is not deemed filed under such provisions, on or after the date of this prospectus until the earlier of the date on which
all of the securities registered hereunder have been sold or the registration statement of which this prospectus is a part has been withdrawn, shall be deemed incorporated by reference in this prospectus and to be a part of this prospectus from the
date of filing of those documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained in a document incorporated or deemed to be incorporated by reference herein
shall be deemed to be modified or superseded, for purposes of this prospectus, to the extent that a statement contained in or omitted from this prospectus, or in any other subsequently filed document that also is or is deemed to be incorporated by
reference herein, modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. Nothing in this prospectus shall be deemed to
incorporate information furnished but not filed with the SEC pursuant to Item&nbsp;2.02 or Item 7.01 of Form 8-K. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon written or oral
request, we will provide, without charge, to each person, including any beneficial owner, to whom a copy of this prospectus is delivered, upon such person&#146;s written or oral request, a copy of any and all of the information incorporated by
reference in this prospectus, other than exhibits to such documents, unless such exhibits are specifically incorporated by reference into the information that this prospectus incorporates. Requests should be directed to the Secretary at Heron
Therapeutics, Inc., 123 Saginaw Drive, Redwood City, California 94063, telephone number (650)&nbsp;366-2626. You may also find these documents in the &#147;Investor Relations&#148; section of our website, <I>www.herontx.com</I>. The information on
our website is not incorporated into this prospectus. We have authorized no one to provide you with any information that differs from that contained in this prospectus. Accordingly, you should not rely on any information that is not contained in
this prospectus. You should not assume that the information in this prospectus is accurate as of any date other than the date of the front cover of this prospectus. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc224932_11"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to the informational requirements of the Exchange Act, and in accordance therewith, files annual, quarterly and special reports, proxy
statements and other information with the SEC. You may read </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and copy any document filed by the Company at the SEC&#146;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on
the public reference room. The Company&#146;s filings with the SEC are also available to the public at the SEC&#146;s Internet web site at <I>http://www.sec.gov</I>. Statements contained in this prospectus as to the contents of any contract or other
document are not necessarily complete, and in each instance we refer you to the copy of the contract or document filed as an exhibit to the registration statement, each such statement being qualified in all respects by such reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;14.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Expenses of Issuance and Distribution.</B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following are the estimated expenses, other than the
underwriting discounts and commissions, relating to the registration of the offer and sale of the securities registered hereunder on Form S-3: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Registration Fee&#151;Securities and Exchange Commission</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accountants Fees and Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">**</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal Fees and Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">**</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer Agent Fees and Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">**</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing Fees and Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">**</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">**</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">**</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">The Company is deferring payment of the registration fee in reliance on Rule&nbsp;456(b) and Rule&nbsp;457(r) under the Securities Act. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">Estimated expenses are not presently known. The foregoing sets forth the general categories of expenses (other than underwriting discounts and commissions) that we anticipate we will incur in connection with the
offering of securities under this registration statement. An estimate of the aggregate expenses in connection with the issuance and distribution of the securities being offered will be included in the applicable prospectus supplement.
</TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;15.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Indemnification of Directors and Officers. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145(a) of the Delaware General
Corporation Law provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative
or investigative (other than an action by or in the right of the corporation), because he or she is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer,
employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in
connection with such action, suit or proceeding, if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding,
had no reasonable cause to believe his or her conduct was unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145(b) of the Delaware General Corporation Law provides,
in general, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor because
the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other
enterprise, against expenses (including attorneys&#146; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if he or she acted in good faith and in a manner he or she reasonably
believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made with respect to any claim, issue or matter as to which he or she shall have been adjudged to be liable to the corporation unless
and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, he or she is fairly and reasonably entitled to indemnity for
such expenses which the Court of Chancery or other adjudicating court shall deem proper. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145(g) of the Delaware General Corporation Law provides, in general, that a
corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of
another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his or her status as such, whether or not the
corporation would have the power to indemnify the person against such liability under Section&nbsp;145 of the Delaware General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s certificate of incorporation provides that, to the extent permitted by applicable law, the Company&#146;s directors shall
not be personally liable to the Company or its stockholders for monetary damages for any breach of fiduciary duty as directors of the Company. The Company&#146;s certificate of incorporation eliminates the personal liability of directors to the
fullest extent permitted by the Delaware General Corporation Law and, together with the Company&#146;s bylaws, provides that the Company shall fully indemnify any person who was or is a party or is threatened to be made a party to any threatened,
pending or completed action, suit, arbitration, alternate dispute resolution mechanism, inquiry, investigation, administrative hearing or other proceeding (whether civil, criminal, administrative, arbitrative or investigative) by reason of the fact
that such person is or was a director or officer of the Company, or is or was serving at the request of the Company as a director or officer of another corporation, partnership, limited liability company, joint venture, trust, employee benefit plan,
foundation, association, organization or other legal entity, against expenses (including attorneys&#146; fees), judgments, damages, liabilities, losses, penalties, excise taxes, fines and amounts paid in settlement actually and reasonably incurred
by such person in connection with such action, suit, arbitration, alternate dispute resolution mechanism, inquiry, investigation, administrative hearing or other proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has also entered into agreements to indemnify its directors and certain officers in addition to the indemnification provided for
in the Company&#146;s certificate of incorporation and bylaws. These agreements, among other things, indemnify the Company&#146;s directors and certain of its officers for certain expenses (including attorneys&#146; fees), judgments, fines and
settlement amounts incurred by such person in any action or proceeding, including any action by or in the right of the Company, on account of services as a director or officer of the Company or as a director or officer, of any subsidiary of the
Company, or as a director or officer of any other company or enterprise that the person provides services to at the request of the Company. We also maintain an insurance policy that covers certain liabilities of directors and officers of our Company
arising out of claims based on acts or omissions in their capacities as directors or officers. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;16.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Exhibit Index. </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Description</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Incorporation, as amended through July&nbsp;29, 2009 (previously filed with the Company&#146;s Quarterly Report on Form 10-Q filed August&nbsp;4, 2009 and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Amendment of Certificate of Incorporation (previously filed with the Company&#146;s Current Report on Form 8-K filed on June&nbsp;30, 2011 and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Amendment of Certificate of Incorporation (previously filed with the Company&#146;s Current Report on Form 8-K filed January&nbsp;13, 2014 and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Bylaws (previously filed with the Company&#146;s Current Report on Form 8-K filed January 22, 2016 and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Copy of Specimen Common Stock Certificate (previously filed with the Company&#146;s Registration Statement on Form S-3 (Registration No. 333-162968) and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Preferred Stock Certificate*</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="91%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Description</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Certificate of Designations*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Warrant Certificate*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Warrant Agreement*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Gibson, Dunn &amp; Crutcher LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>12.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Statement Regarding Computation of Ratio of Earnings to Fixed Charges*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of OUM &amp; Co. LLP, the Company&#146;s independent registered public accounting firm</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Gibson, Dunn &amp; Crutcher LLP (included in legal opinion filed as Exhibit 5.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (included on signature page)</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">To be filed, if necessary, subsequent to the effectiveness of this registration statement as an exhibit to (i)&nbsp;a report filed under the Exchange Act to be incorporated by reference herein or (ii)&nbsp;a
post-effective amendment hereto, as applicable. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;17.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Undertakings. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">To include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act of 1933; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a
fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was
registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price
represent no more than 20 percent change in the maximum aggregate offering price set forth in the &#147;Calculation of Registration Fee&#148; table in the effective registration statement. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>provided</I>,<I> however</I>, that paragraphs (1)(i), (1)(ii)&nbsp;and (1)(iii)&nbsp;of this section do not apply if the
information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Securities Exchange
Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) under the Securities Act that is part of the registration statement. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and
the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">If the registrant is relying on Rule 430B under the Securities Act: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top">Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in this registration
statement; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or
(x)&nbsp;for the purpose of providing the information required by Section&nbsp;10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is
first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter,
such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the
initial <I>bona fide</I> offering thereof. <I>Provided, however</I>, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference
into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration
statement or prospectus that was part of this registration statement or made in any such document immediately prior to such effective date. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities: </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration
statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to
the purchaser and will be considered to offer or sell such securities to such purchaser: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of
the registrant&#146;s annual report pursuant to Section&nbsp;13(a) or 15(d) of the Securities Exchange Act (and, where applicable, each filing of an employee benefit plan&#146;s annual report pursuant to Section&nbsp;15(d) of the Securities Exchange
Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial
<I>bona fide</I> offering thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act, as amended, may be
permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses
incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being
registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as
expressed in the Securities Act and will be governed by the final adjudication of such issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby
undertakes that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) For purposes of determining any liability under the Securities Act, the information omitted from the
form of prospectus filed as part of this registration statement in reliance upon Rule 430A under the Securities Act and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities
Act shall be deemed to be part of this registration statement as of the time it was declared effective. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) For the
purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the Company certifies that it has reasonable grounds to believe that
it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Redwood City, California, on July 29, 2016. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Heron Therapeutics, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Brian G. Drazba</I></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brian G. Drazba</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Vice President, Finance and
Chief Financial Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KNOW ALL PERSONS BY THESE PRESENTS that each individual whose signature appears below hereby constitutes and appoints Brian G. Drazba and
David L. Szekeres, and each of them acting individually, as his true and lawful attorney-in-fact and agent, with full power of substitution, for him and in his name, place and stead, in any and all capacities, to sign this registration statement and
any and all amendments thereto, including post-effective amendments, and to file the same, with all exhibits thereto, any related registration filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and other documents in
connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises,
as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all the said attorney-in-fact and agent or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form S-3 has been signed by the
following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>Signature</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>Title</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>Date</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Barry D. Quart</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Barry D. Quart, Pharm. D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer, Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Principal Executive Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;29, 2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian G. Drazba</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Brian G. Drazba</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Vice President, Finance and Chief Financial Officer (Principal Financial and Accounting Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;29, 2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Craig A. Johnson</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Craig A. Johnson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;29, 2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John W. Poyhonen</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">John W. Poyhonen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;29, 2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robert H. Rosen</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Robert H. Rosen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">President, Chief Commercial Officer, Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;29, 2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kevin C. Tang</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Kevin C. Tang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chairman of the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;29, 2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Christian Waage</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Christian Waage </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;29, 2016</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Description</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Incorporation, as amended through July&nbsp;29, 2009 (previously filed with the Company&#146;s Quarterly Report on Form 10-Q filed August&nbsp;4, 2009 and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Amendment of Certificate of Incorporation (previously filed with the Company&#146;s Current Report on Form 8-K filed on June&nbsp;30, 2011 and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Amendment of Certificate of Incorporation (previously filed with the Company&#146;s Current Report on Form 8-K filed January&nbsp;13, 2014 and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Bylaws (previously filed with the Company&#146;s Current Report on Form 8-K filed January 22, 2016 and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Copy of Specimen Common Stock Certificate (previously filed with the Company&#146;s Registration Statement on Form S-3 (Registration No. 333-162968) and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Preferred Stock Certificate*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Certificate of Designations*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Warrant Agreement*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Warrant Certificate*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Gibson, Dunn &amp; Crutcher LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>12.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Statement Regarding Computation of Ratio of Earnings to Fixed Charges*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of OUM &amp; Co. LLP, the Company&#146;s independent registered public accounting firm</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Gibson, Dunn &amp; Crutcher LLP (included in legal opinion filed as Exhibit 5.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (included on signature page)</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">To be filed, if necessary, subsequent to the effectiveness of this registration statement as an exhibit to (i)&nbsp;a report filed under the Exchange Act to be incorporated by reference herein or (ii)&nbsp;a
post-effective amendment hereto, as applicable. </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d224932dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[LETTERHEAD OF GIBSON, DUNN&nbsp;&amp; CRUTCHER LLP] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July 29, 2016 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Heron Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">123 Saginaw Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Redwood City, CA 94063 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top">Heron Therapeutics, Inc. </TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Registration Statement on Form S-3 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as special counsel to
Heron Therapeutics, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), in connection with the preparation and filing with the Securities and Exchange Commission (the &#147;<U>Commission</U>&#148;) of a Registration Statement on Form S-3
(the &#147;<U>Registration Statement</U>&#148;) under the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;), relating to the registration under the Securities Act and the proposed issuance and sale from time to time pursuant
to Rule 415 under the Securities Act, together or separately and in one or more series (if applicable) of: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) shares of the
Company&#146;s common stock, par value $0.01 per share (the &#147;<U>Common Stock</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) shares of the Company&#146;s preferred
stock, par value $0.01 per share (the &#147;<U>Preferred Stock</U>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) warrants for the purchase of Common Stock and
Preferred Stock (the &#147;<U>Warrants</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Common Stock, the Preferred Stock, and the Warrants are collectively referred to
herein as the &#147;<U>Securities</U>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In arriving at the opinions expressed below, we have examined originals, or copies certified or otherwise
identified to our satisfaction as being true and complete copies of the originals, of specimen Common Stock certificates and such other documents, corporate records, certificates of officers of the Company and of public officials and other
instruments as we have deemed necessary or advisable to enable us to render these opinions. In our examination, we have assumed the genuineness of all signatures, the legal capacity and competency of all natural persons, the authenticity of all
documents submitted to us as originals and the conformity to original documents of all documents submitted to us as copies. As to any facts material to these opinions, we have relied to the extent we deemed appropriate and without independent
investigation upon statements and representations of officers and other representatives of the Company and others. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have assumed without independent investigation that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) at the time any Securities are sold pursuant to the Registration Statement (the &#147;<U>Relevant Time</U>&#148;), the Registration
Statement and any supplements and amendments thereto (including post-effective amendments) will be effective and will comply with all applicable laws; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) at the Relevant Time, a prospectus supplement will have been prepared and filed with the Commission describing the Securities offered
thereby and all related documentation and will comply with all applicable laws; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) all Securities will be issued and sold in the
manner stated in the Registration Statement and the applicable prospectus supplement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) at the Relevant Time, all corporate or other
action required to be taken by the Company to duly authorize each proposed issuance of Securities and any related documentation (including (i)&nbsp;the due reservation of any shares of Common Stock or Preferred Stock for issuance upon exercise,
conversion or exchange of any Securities for Common Stock or Preferred Stock (a &#147;<U>Convertible Security</U>&#148;), and (ii)&nbsp;the execution (in the case of certificated Securities), delivery and performance of the Securities and any
related documentation referred to in paragraphs 1 through 3 below) shall have been duly completed and shall remain in full force and effect; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(v) upon issuance of any Common Stock or Preferred Stock, including upon exercise, conversion or exchange of any Convertible Security, the
total number of shares of Common Stock or Preferred Stock issued and outstanding will not exceed the total number of shares of Common Stock or Preferred Stock, as applicable, that the Company is then authorized to issue under its certificate of
incorporation and other relevant documents; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vi) at the Relevant Time, a definitive purchase, underwriting or similar agreement and
any other necessary agreement with respect to any Securities offered or issued will have been duly authorized by all necessary corporate or other action of the Company duly executed and delivered by the Company and the other parties thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the foregoing and in reliance thereon, and subject to the assumptions, exceptions, qualifications and limitations set forth herein, we are of the
opinion that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">With respect to shares of Common Stock, when: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such shares of Common Stock have been duly executed (in the case of certificated shares) and delivered either
(i)&nbsp;in accordance with the applicable definitive purchase, underwriting or similar agreement for the consideration provided for therein, or (ii)&nbsp;upon conversion or exercise of any Convertible Security, in accordance with the terms of such
Convertible Security or the instrument governing such Convertible Security providing </P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="21%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
for such conversion or exercise, and for any additional consideration specified therein, which consideration (including any consideration paid for such Convertible Security), on a per-share
basis, shall in either event not be less than the par value of the Common Stock, and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">any such Convertible Security was previously validly issued and is fully paid and non-assessable or is a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms,
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">such shares of Common Stock will be validly issued, fully paid and non-assessable. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">With respect to any shares of Preferred Stock, when: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">the certificate of designations relating to such Preferred Stock (the &#147;<U>Certificate of Designations</U>&#148;) has been duly executed and filed with the Office of the Secretary of State of the State of Delaware,
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">such shares have been issued either (i)&nbsp;in accordance with the applicable definitive purchase, underwriting or similar agreement and for the consideration therefor provided for therein or (ii)&nbsp;upon exercise,
conversion or exchange of any Convertible Security and for any additional consideration specified in such Convertible Security or the instrument governing such Convertible Security providing for such conversion or exercise, which consideration
(including any consideration paid for such Convertible Security), on a per-share basis, shall in either event not be less than the par value of the Preferred Stock, and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">any such Convertible Security was previously validly issued and is fully paid an non-assessable or is a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms,
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">such shares of Preferred Stock will be validly issued, fully paid and non-assessable. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">With respect to any Warrants, when: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">the warrant agreement relating to such Warrants (the &#147;<U>Warrant Agreement</U>&#148;), if any, has been duly executed and delivered by the Company and each other party thereto, </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">the terms of the Warrants have been established in accordance with the Warrant Agreement, if any, and the applicable definitive purchase, underwriting or similar agreement, and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">the Warrants have been duly executed (in the case of certificated Warrants) and delivered in accordance with the Warrant Agreement, if any, and the applicable definitive purchase, underwriting or similar agreement for
the consideration provided for therein, </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">such Warrants will be legal, valid and binding obligations of the Company, enforceable against the Company in
accordance with their terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The opinions expressed above are subject to the following exceptions, qualifications, limitations and assumptions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">A. We render no opinion herein as to matters involving the laws of any jurisdiction other than the State of New York and the United States of
America and, for purposes of paragraphs 1 and 2 above, the Delaware General Corporation Law. We are not admitted to practice in the State of Delaware; however, we are generally familiar with the Delaware General Corporation Law as currently in
effect and have made such inquiries as we consider necessary to render the opinions contained in paragraphs 1 and 2 above. Without limitation, we do not express any opinion regarding any Delaware contract law. This opinion is limited to the effect
of the current state of the laws of the State of New York, the United States of America and, to the limited extent set forth above, the laws of the State of Delaware and the facts as they currently exist. We assume no obligation to revise or
supplement this opinion in the event of future changes in such laws or the interpretations thereof or such facts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">B. The opinions above
with respect to the Warrants and the Warrant Agreement (collectively, the &#147;<U>Documents</U>&#148;) are each subject to (i)&nbsp;the effect of any bankruptcy, insolvency, reorganization, moratorium, arrangement or similar laws affecting the
rights and remedies of creditors&#146; generally, including without limitation the effect of statutory or other laws regarding fraudulent transfers or preferential transfers, and (ii)&nbsp;general principles of equity, including without limitation
concepts of materiality, reasonableness, good faith and fair dealing and the possible unavailability of specific performance, injunctive relief or other equitable remedies regardless of whether enforceability is considered in a proceeding in equity
or at law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">C. We express no opinion regarding the effectiveness of (i)&nbsp;any waiver of stay, extension or usury laws;
(ii)&nbsp;provisions relating to indemnification, exculpation or contribution, to the extent such provisions may be held unenforceable as contrary to public policy or federal or state securities laws or due to the negligence or willful misconduct of
the indemnified party; (iii)&nbsp;any provision in any Document waiving the right to object to venue in any court; (iv)&nbsp;any agreement to submit to the jurisdiction of any Federal court; (v)&nbsp;any waiver of the right to jury trial or
(vi)&nbsp;any provision to the effect that every right or remedy is cumulative and may be exercised in addition to any other right or remedy or that the election of some particular remedy does not preclude recourse to one or more others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">D. To the extent relevant to our opinion in paragraph 3 and not covered by our opinions in paragraphs 1 or 2, we have assumed that any
securities underlying, comprising or issuable upon exchange, conversion or exercise of any Warrants are validly issued, fully paid and non-assessable (in the case of an equity security) or a legal, valid and binding obligation of the issuer thereof,
enforceable against such issuer in accordance with its terms. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You have informed us that you intend to issue Securities from time to time on a delayed or continuous basis, and
we understand that prior to issuing any Securities pursuant to the Registration Statement (i)&nbsp;you will advise us in writing of the terms thereof, and (ii)&nbsp;you will afford us an opportunity to (x)&nbsp;review the operative documents
pursuant to which such Securities are to be issued or sold (including the applicable offering documents), and (y)&nbsp;file such supplement or amendment to this opinion (if any) as we may reasonably consider necessary or appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the filing of this opinion as an exhibit to the Registration Statement, and we further consent to the use of our name under the caption
&#147;Legal Matters&#148; in the Registration Statement and the prospectus that forms a part thereof. In giving these consents, we do not thereby admit that we are within the category of persons whose consent is required under Section&nbsp;7 of the
Securities Act or the rules and regulations of the Commission promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ GIBSON, DUNN&nbsp;&amp; CRUTCHER LLP </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d224932dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement on Form S-3 of Heron Therapeutics,
Inc. of our reports dated February 18, 2016 relating to the consolidated financial statements and the effectiveness of internal control over financial reporting of Heron Therapeutics, Inc. appearing in the Company&#146;s Annual Report on Form 10-K
for the year ended December 31, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also consent to the reference to us under the caption &#147;Experts&#148; in the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ OUM &amp; CO. LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July 29, 2016 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g224932g04j69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g224932g04j69.jpg
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ML]/5-#514U1787:!EK*TM=8D)3,W0G%R<['!"3ABAI&AMM%#4E6%I</2_]H
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M9'9>3L"RID4U')O5$&7%BIXJG36;:Q\%WBIM?Q+M:%$+@:3O"V!JQ9J_=*W
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MH.+:EU/7ST.K]4\3>S]GJ,W-U]B+P5Z<HG>=E[DDSA9=U5&2:RPM<58MS<,
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M=G4S682I3B:!<P5>N0D'B$)1!!$+,Q7!P)-)S7R 1*^?AX6_V^'G-_EC#_\
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MWUN)'K[< N)9F(TF6D58CY!\0J50PA\-SV)/L5NL>LA2<\Z\GNJ[1R>'PM?
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M-G?W>U(O0:W[Z.=_&.S/[NZQWM2'FK+VTZ\AT_8\E6RUZ-V>0/=HN-J=D,E
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M"AAB;*I*&(<HHD&J:(&!#,3&H^DV2$V7W9UV[1)(*TQVI-2;%1?9J$):DH2
ME+K)5X2 @"I4-3P*9\I,488J(P_DUH%I9+C24-N>K$SNULUU+Q$XIR[R=OX#
M,1E;-4Q=6JOR3JBZM1EA<DKTLXKL9->#EHK&3(8B)XAYW:N<ZGX8L2]=].W=
MOYF,M9JF+ZM1^3=454J,L+DE>EG"&,FO!2T5#)D,1!<=YWC_  .UW^.S2/\
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9G\F&I]<M?5N:<::<::<::<::<::<::__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
